Apollomics, Inc.
NASDAQ:APLMBiotechnology
Healthcare
$17.84 +34.72%
+$6.03 today
- Market cap
- $52.00M
- Beta
- 1.45
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$25.98
52W Low $3.66High $42.12
Volume 0.02M
Average 0.02M
Income Statement
Follow revenue through to earnings.
Revenue
$8.50M
FY 2025 · Annual
+4192.9% YoYOperating Income
-$9.47M
FY 2025 · Annual
Net Income
-$10.94M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2K | 323K | 821K | 198K | 8.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 255K |
| Gross Profit | 2K | 323K | 821K | 198K | 8.25M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.0% |
| Research & Development | 35.57M | 35.46M | 34.19M | 24.57M | 5.53M |
| Selling, General & Admin | 15.29M | 9.95M | 20.64M | 17.77M | 12.44M |
| Operating Expenses | 50.86M | 45.4M | 54.83M | 42.33M | 17.72M |
| Depreciation & Amortization | 153K | 182K | 103K | 72K | 255K |
| EBITDA | (50.12M) | (43.88M) | (53.45M) | (41.06M) | (9.22M) |
| EBITDA Margin | -2505850.0% | -13586.1% | -6509.9% | -20734.8% | -108.4% |
| Operating Income | (50.86M) | (45.08M) | (54.01M) | (42.14M) | (9.47M) |
| Operating Margin | -2542850.0% | -13957.0% | -6578.9% | -21280.8% | -111.4% |
| Interest Income | 467K | 431K | 753K | 480K | 152K |
| Interest Expense | 83K | 93K | 150K | 179K | 65K |
| Other Income / Expenses | (43.94M) | (195.73M) | (118.58M) | (11.46M) | (1.46M) |
| Income Before Tax | (94.8M) | (240.81M) | (172.59M) | (53.6M) | (10.94M) |
| Pre-Tax Margin | -4739800.0% | -74554.2% | -21022.0% | -27070.2% | -128.7% |
| Income Tax Expense | 1K | 1K | 10K | 259K | 3K |
| Net Income | (94.8M) | (240.81M) | (172.6M) | (53.86M) | (10.94M) |
| Net Margin | -4739850.0% | -74554.5% | -21023.3% | -27201.0% | -128.7% |
| EPS (Basic) | (23.45) | (61.60) | (231.99) | (52.80) | (7.57) |
| EPS (Diluted) | (23.45) | (61.60) | (231.99) | (52.80) | (7.57) |
| 867.96K | 867.96K | 743.97K | 926.47K | 1.45M | |
| 867.96K | 867.96K | 743.97K | 926.47K | 1.45M |
APLM Earnings Waterfall · TTM
NASDAQ:APLM · Revenue to Net Income
Key Ratios
EPS$-62.49
Gross Margin75.0%
Net Margin-237.7%
P/E Ratio0.2
P/S Ratio1.3
Analysis
$8.7M of revenue converted into -$64.8M of net income for the selected period. Gross margin is 75.0% and net margin is -237.7%, showing how much revenue survives after costs and taxes. EPS is $-62.49, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 6, 2026 | |
| 4/A | 4/A filing | Sep 24, 2026 | |
| 4/A | 4/A filing | Sep 24, 2026 | |
| 4/A | 4/A filing | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 |
How much revenue does APLM generate?
Apollomics, Inc. (APLM) reported $8.50M of revenue in fiscal 2025.
Is APLM profitable?
Apollomics, Inc. (APLM) reported -$10.94M of net income, with a net margin of -128.7%.
Continue the stock analysis
Jump to another research area for this company.